Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Fasenra (Benralizumab) Inj 30 Mg (CDM 3051826) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved November 17, 2026 , from http://ppman.hank.ai/transparency/procedure/3051826/by-state?code_type=CDM
“Fasenra (Benralizumab) Inj 30 Mg (CDM 3051826) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/3051826/by-state?code_type=CDM. Accessed
November 17, 2026 .
“Fasenra (Benralizumab) Inj 30 Mg (CDM 3051826) by State,” HANK Price Transparency ,
accessed November 17, 2026 ,
http://ppman.hank.ai/transparency/procedure/3051826/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
3051826 — Fasenra (Benralizumab) Inj 30 Mg
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$13,922
National median
$11,322 – $13,922
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 3051826 (CDM), with interquartile range
State Median p25 p75
MS $13,922 $11,322 $13,922